Article Information
History
- July 30, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Yayquier Díaza,
- Mayra Ramos-Suzarteb,*,
- Yordanis Martína,
- Néstor Antonio Calderóna,
- William Santiagoa,
- Orlando Viñeta,
- O Yulieski Laa,
- Jorge Pérez,
- Augusto Oyarzábala,
- Yoan Péreza,
- Geidy Lorenzob,
- Meylan Cepedab,
- Danay Saavedrab,
- Zaima Mazorrab,
- Daymys Estevezb,
- Patricia Lorenzo-Luacesb,
- Carmen Valenzuelab,
- Armando Caballeroc,
- Kalet Leonb,
- Tania Crombetb and
- Carlos Jorge Hidalgoa
- aManuel Fajardo Universitary Hospital, Santa Clara, Villa Clara, Cuba
- bCenter of Molecular Immunology, Playa, La Habana, Cuba
- cArnaldo Milian Castro Universitary Hospital. Santa Clara, Villa Clara. Cuba
- ↵*Corresponding Author:
Mayra Ramos Suzarte PhD. Prof., Clinical Research Direction, Center of Molecular Immunology, Ave 216, Esq. 15. Atabey., Playa, Havana, 11600. Cuba, Phone number: +5372143146 +5353310380, mayra{at}cim.sld.cu
Yayquier Díaz and Mayra Ramos-Suzarte have contributed equally to this article
Posted July 30, 2020.
Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19
